Table 9

Risks associated with discouraging participation in HIV cure research

Very likely to discourage
N (%)
Somewhat likely to discourage
N (%)
Not likely to discourage
N (%)
Not discouraging
N (%)
DNK
N (%)
DNA
N (%)
Missing
N (%)
Toxicities/adverse side effects35 (30)12 (10)14 (12)3 (3)17 (14)10 (9)27 (23)
Potential for drug resistance development31 (26)11 (9)13 (11)5 (4)19 (16)15 (13)24 (20)
Potential for virus returning if ART is stopped31 (26)9 (8)7 (6)5 (4)25 (21)14 (12)27 (23)
Activation of cancer-causing genes27 (23)5 (4)13 (11)3 (3)28 (24)14 (12)28 (24)
GVHD29 (25)8 (7)9 (8)3 (3)28 (24)12 (10)29 (25)
Invasive study procedures25 (21)10 (9)7 (6)9 (8)20 (17)12 (10)35 (30)
Long-term follow-up for safety and outcomes28 (24)12 (10)10 (9)8 (7)24 (20)10 (9)26 (22)
Neurological side effects23 (20)18 (15)10 (9)5 (4)17 (14)16 (14)29 (25)
Gastrointestinal side effects26 (22)17 (14)10 (9)7 (6)18 (16)15 (13)25 (21)
Psychological side effects29 (25)17 (14)9 (8)7 (6)17 (14)13 (11)26 (22)
HIV-related side effects33 (28)14 (12)8 (7)7 (6)20 (17)15 (13)21 (18)
Dermatological side effects37 (31)14 (12)5 (4)6 (5)21 (18)13 (11)22 (19)
Musculoskeletal side effects33 (28)15 (13)9 (8)6 (5)15 (13)14 (12)26 (22)
Allergic reactions29 (25)13 (11)11 (9)3 (3)15 (13)17 (14)30 (25)
Risk of giving HIV to sexual partners32 (27)10 (9)11 (9)2 (2)18 (15)13 (11)32 (27)
Unknown side effects26 (22)11 (9)6 (5)3 (3)22 (13)19 (16)31 (26)
Pain or discomfort28 (24)13 (11)4 (3)3 (3)21 (18)19 (16)30 (25)
Having to stay in hospital overnight18 (16)12 (10)10 (9)12 (10)19 (16)19 (16)28 (24)
Taking time away from family19 (16)13 (11)12 (10)9 (8)14 (12)23 (20)28 (24)
Taking time away from work20 (17)11 (9)11 (9)12 (10)16 (14)20 (17)28 (24)
Long study visits (4+ hours)22 (19)11 (9)12 (10)11 (9)17 (14)19 (16)26 (22)
  • DNA, does not apply; DNK, do not know.